ASPEQ Heating Group
Purchase-Price Allocation
Goodwill
$195.0M
Assets Acquired
$490.9M
18 years of history · ending 2025-12-31 · SEC EDGAR
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | 1.80% | 0.40% | 9.60% | 3.50% | 3.60% | 2.60% |
| Foreign Rate Differential | -4.60% | 12.60% | -9.70% | 0.60% | 1.40% | — |
| Other Adjustments | -1.30% | -3.00% | -1.80% | -0.10% | 0.00% | -0.30% |
| R&D Tax Credits | — | — | — | — | — | 1.30% |
| SBC (Nondeductible) | — | — | — | — | — | -2.40% |
| Nondeductible Expenses | 2.20% | 3.30% | 7.70% | 2.00% | 1.20% | — |
| Valuation Allowance Change | -0.60% | 47.90% | -19.60% | -1.00% | -0.40% | — |
| Effective Tax Rate | 6.10% | 15.60% | 26.90% | 22.30% | 21.00% | 21.80% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | $4.8M | $10.9M | $7.3M | $41.6M | $53.6M | $68.6M |
| Income Taxes Paid (Cash) | $7.6M | −$5.5M | −$59.6M | $58.4M | $43.5M | $57.3M |
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Purchase-Price Allocation
Goodwill
$195.0M
Assets Acquired
$490.9M
Purchase-Price Allocation
Goodwill
$142.4M
Assets Acquired
$345.1M
Deferred Tax Liability
$37.1M
Purchase-Price Allocation
Goodwill
$104.4M
Assets Acquired
$360.9M
Purchase-Price Allocation
Goodwill
$77.4M
Assets Acquired
$173.3M
Per-category restructuring disclosures sourced from us-gaap:RestructuringCostAndReserveAxis dimensional XBRL. Negative charges indicate reversals of prior accruals (a sign the original estimate was too aggressive — flattering current-period earnings).
As of 2025-12-31
| Category | Class | P&L Charge | Cash Paid | Reserve Balance |
|---|---|---|---|---|
| Facility Closing | Facility Closing | — | — | — |
Phase 1: currency selection stored in the URL. Conversion ships in Phase 2 (see ADR-0003).